

# Effect of imidazole receptor active agents on porcine myometrial contractility

Dong-ho Shin, Seung-young Nah, Jae-ha Kim\*

College of Veterinary Medicine and College of Medicine\*  
Chonnam National University

(Received Apr 5, 1997)

## 돼지의 자궁근 수축성에 대한 몇가지 imidazole receptor active agents의 효과

신동호 · 나승열 · 김재하\*

전남대학교 수의과대학, 의과대학\*

(1997년 4월 5일 접수)

**초 록 :** 최근 동물의 진통 및 진정을 목적으로 널리 사용되고 있는 imidazole 유도체인 clonidine, medetomidine, etomidate 등의 약물과 xylazine의 효과를 발정정지기의 척출 돼지 자궁근에서 검토하였다. Clonidine( $10^{-8}$ ~ $10^{-6}$ M)이나 medetomidine( $10^{-8}$ ~ $10^{-6}$ M)은 xylazine과 비슷한 정도로 용량 의존적인 자궁근의 수축을 일으켰다. Clonidine, medetomidine, xylazine 등의  $EC_{50}$ 는 각각 24.7nM, 19.9nM, 45.1nM이었다. 그러나 etomidate는  $10^{-6}$ M 미만의 농도에서 반응이 거의 없었으며,  $10^{-6}$ M 이상에서 수축반응을 일으켰다.

이들 agonists의 효과는 yohimbine( $10^{-8}$ ~ $10^{-6}$ M), idazoxan( $10^{-7}$ ~ $10^{-5}$ M), tolazoline( $10^{-7}$ ~ $10^{-5}$ M) 등의  $\alpha_2$ -adrenoceptor antagonists에 의해서 차단되었으나,  $\alpha_1$ -adrenoceptor antagonist인 prazosin ( $10^{-6}$ M)에 의해서는 차단되지 않았다. 또한  $Ca^{2+}$ -free medium이나 verapamil( $10^{-5}$ M)의 전처치에 의해서 이들 agonist의 효과가 완전히 차단되었다.

결론적으로 발정정지기의 돼지 자궁근에서 clonidine, medetomidine, etomidate, xylazine 등은  $\alpha_2$ -adrenoceptors의 흥분을 통해 자궁근의 수축을 일으키며, 이 효과는 voltage-dependent  $Ca^{2+}$  channels을 통한 extracellular  $Ca^{2+}$  influx의 증가에 의한 것으로 추론하였다.

**Key words :** myometrium, clonidine, medetomidine, etomidate, xylazine.

### Introduction

Clonidine, medetomidine, and etomidate are imidazole

compounds and clonidine and medetomidine bind to  $\alpha_2$ -adrenoceptors as well as non-adrenergic imidazole receptors<sup>1-5</sup>. These imidazole compounds can cause the effects that resemble those of xylazine, an  $\alpha_2$ -adrenoceptor agonist. Xy-

This paper was supported by Non Directed Research Fund, Korea Research Foundation.

Address reprint requests to Dr. Dong-ho Shin, College of Veterinary Medicine, Chonnam National University, Kwangju 500-757, Republic of Korea.

lazine, clonidine, medetomidine, and etomidate are frequently used as analgesics or sedatives in veterinary medicine<sup>6-9</sup>. These agents also cause various adverse effects such as bradycardia, heartblock, hypotension, ruminal atony, mydriasis, hyperglycemia, and abortion<sup>10-13</sup>.

Agents which increase the myometrial contractility can be used to prevent the delayed parturition due to uterine inertia, especially in polytocous animals as sows, to reduce the postpartum bleeding, and to shorten the time of uterine involution. Both  $\alpha_1$ - and  $\alpha_2$ -adrenoceptors have been identified in the myometrial smooth muscles<sup>14,15</sup> and recent studies describe  $\alpha_2$ -adrenoceptors as well as  $\alpha_1$ -adrenoceptors may also mediate the increase in uterine contractility<sup>16-18</sup>.

In the present study, we evaluated the effect of three imidazole compounds on myometrial contractility by comparing with that of xylazine. We determined the difference of drug potency among agonists and also compared the potency of antagonists in blocking these effects of agonists. We also determined whether  $\text{Ca}^{3+}$ -free medium or verapamil, a voltage-dependent  $\text{Ca}^{2+}$  channel blocker, can abolish the effect of these agents.

## Materials and Methods

**Uterine strips :** Uteri from sows were obtained from a local slaughter house. We used only uteri from the diestrus (days 12~15) period, which was determined through visual inspection of the ovary. They have the corpus luteum that were dark red to wine red at this stage<sup>19</sup>. Uteri were trimmed of connective tissue and endometrium and then stored in ice-cold Tyrode's solution that was aerated with 95%  $\text{O}_2$  and 5%  $\text{CO}_2$ . The tissues were used for experiments within 10 hr of collection. Ages and breeds of the sows could not be determined.

**Experimental condition :** Longitudinal uterine strips (2cm  $\times$  0.2cm) were mounted in 10ml water-jacketed tissue baths. The tissue was maintained at 37°C in the Tyrode's solution (137mM NaCl, 2mM KCl, 1mM  $\text{CaCl}_2$ , 0.4mM  $\text{MgCl}_2$ , 12mM  $\text{NaHCO}_3$ , 11mM dextrose, pH 7.4) aerated with a mixture of 95%  $\text{O}_2$  and 5%  $\text{CO}_2$ . The  $\text{Ca}^{2+}$ -free Tyrode's solution was made by omitting 1mM  $\text{CaCl}_2$  from

the above solution. In the experiment using  $\text{Ca}^{2+}$ -free Tyrode's solution, we washed strips with a  $\text{Ca}^{2+}$ -free Tyrode's solution for three times and then bathed in this  $\text{Ca}^{2+}$ -free solution before the administration of the agonist. Agonist was given 10 min after the replacement with a  $\text{Ca}^{2+}$ -free Tyrode's solution.

The force developed by the strips were recorded through a Grass FT 03 force displacement transducer connected to a Grass Model 79 recorder. The contractile force was quantified by integrating the area under the tension versus time curve using a scanning program (SigmaScan, Jandel, Corte Madera, CA). All strips were initially exposed to hyperosmotic 140mM KCl for 2 min because this dose of KCl causes near maximal contractions. The contractile responses were expressed as the percentage of the response to hyperosmotic 140mM KCl. The experiments were performed under a resting tension of 2g and the strips were allowed to equilibrate for at least 30 min before experiments were begun and after 'washed out' during experiments. Agonist treatments were made at 10-min intervals in a cumulative dose schedule and only the 2-min maximal responses were compared. In all experiments, different uterine strips from the same uterus were randomly assigned to all treatment groups in one trial and one uterus was used for one trial only.

**Drugs :** The following drugs were purchased from Sigma Chemical Co. : xylazine HCl, clonidine HCl, prazosin HCl, yohimbine HCl, idazoxan HCl, tolazoline HCl, verapamil HCl and carbachol chloride. Medetomidine HCl and etomidate HCl were donated by Dr. W.H. Hsu. Iowa State University (Ames, IA).

**Statistical analyses :** Results were presented as mean  $\pm$  SEM. Differences between means were determined by Student's *t*-test for grouped observations. The significance level was set at  $p < 0.05$ .

## Results

**Effects of agonists on myometrial contractility :** Clonidine ( $10^{-8}$ ~ $10^{-6}$ M) and medetomidine ( $10^{-8}$ ~ $10^{-6}$ M) caused a dose-dependent increase in contractility of luteal phase myometrium and the contractile effect of these two im-




Fig 1. The contractile effects of clonidine(○), medetomidine (●), and xylazine(▽) in isolated porcine myometrial strips in the luteal phase of the estrous cycle(n=7.12), \*p < 0.05), compared with the corresponding dose of xylazine.

idazole compounds were similar to that of xylazine(Fig 1). The EC<sub>50</sub> of clonidine, medetomidine, and xylazine were 24. 7nM, 19.9nM, and 45.1nM, respectively.

Etomidate, interestingly, did not cause any increase in contractility in our present study at less than 10<sup>-6</sup>M. However, a higher dose of etomidate(10<sup>-6</sup>M) caused an increase in contractility(46.4 ± 3.16, n=8).

Effects of antagonists on agonist-induced myometrial contractions : The effects of clonidine, medetomidine, and xylazine were inhibited by pretreatment with α<sub>2</sub>-adrenoceptor antagonists such as yohimbine, idazoxan, and tolazoline. Yohimbine was most potent in antagonizing the effects of agonists in the present study(Figs 2~4). However, prazosin (10<sup>-6</sup>M), an α<sub>1</sub>-adrenoceptor antagonist, failed to block the effect of clonidine, medetomidine, and xylazine(Table 1). In addition, the effect of etomidate(43.7 ± 6.1, n=3) was blocked by 10<sup>-7</sup>M yohimbine(1.7 ± 1.7, n=3), 10<sup>-6</sup>M idazoxan(0, n =3), and 10<sup>-6</sup>M tolazoline(0, n=3), but prazosin(10<sup>-6</sup>M) did not block the effect of etomidate(44.6 ± 4.8, n=3).

Effects of Ca<sup>2+</sup>-free medium and verapamil on agonist-induced myometrial contractions : Ca<sup>2+</sup>-free medium was used to determine if the effects of clonidine, medetomidine, etomidate, xylazine, and carbachol on myometrial contractions were mediated by extracellular Ca<sup>2+</sup>, Ca<sup>2+</sup>-free

Table 1. Effect of prazosin(10<sup>-6</sup>M) on clonidine-, medetomidine-, etomidate-, and xylazine-induced increase in contractility in isolated porcine myometrial strips in the luteal phase of the estrous cycle(n=4)

Pretreatment	Agonist concentration, -log[M]				
	8	7.5	7	6.5	6
None prazosin	30.8 ± 3.6	56.8 ± 2.6	76.1 ± 3.7	94.3 ± 3.7	106.2 ± 2.4
	20.0 ± 6.0	54.2 ± 5.9	76.2 ± 8.6	102.2 ± 10.2	122.6 ± 10.9
none prazosin	35.3 ± 2.2	61.5 ± 2.7	78.2 ± 2.8	97.3 ± 2.3	112.0 ± 2.1
	37.3 ± 4.6	59.4 ± 4.4	74.3 ± 4.2	89.1 ± 2.8	103.9 ± 2.7
none prazosin	19.8 ± 3.4	41.1 ± 3.9	61.7 ± 6.1	85.6 ± 5.2	100.7 ± 3.7
	31.0 ± 7.6	53.6 ± 7.0	76.2 ± 4.8	95.4 ± 12.1	106.5 ± 7.9

Table 2. Effect of Ca<sup>2+</sup>-free medium and verapamil(10<sup>-5</sup>M) on clonidine(CLO)-, medetomidine(MED)-, etomidate(ETO)-, xylazine(XYL)-, and carbachol(CAR)- induced increase in contractility in isolated porcine myometrial strips in the luteal phase of the estrous cycle(n=4)

Pretreatment	Agonist(10 <sup>-6</sup> M)				
	CLO	MED	ETO	XYL	CAR
none Ca <sup>2+</sup> -free ± 0*	88.1 ± 4.4	101.0 ± 3.4	37.0 ± 5.6	84.8 ± 4.6	157.7 ± 3.9
	0*	0*	0*	0*	102.9 ± 4.6*
none verapamil	106.8 ± 8.4	102.4 ± 3.4	59.9 ± 3.7	89.4 ± 5.3	147.2 ± 8.7
	4.2 ± 1.2*	1.0 ± 1.0*	1.4 ± 1.4*	2.6 ± 1.6*	84.4 ± 5.0*

\*p < 0.05 : compared with the control(none) group.


medium completely prevented the contractile effects of clonidine, medetomidine, etomidate, and xylazine, but it significantly reduced the effect of carbachol (Table 2).

Verapamil ( $10^{-5}$ M) was used to determine whether this voltage-dependent  $Ca^{2+}$  channel blocker would abolish the effect of agonists. Verapamil completely prevented the contractile effects of clonidine, medetomidine, etomidate, and xylazine, but it significantly reduced the effect of carbachol

(Table 2).

## Discussion

Clonidine ( $10^{-8}$ – $10^{-6}$ M) and medetomidine ( $10^{-8}$ – $10^{-6}$ M) caused a dose-dependent increase in contractility of luteal phase myometrium. The contractile effects of these two imidazole compounds were similar to that of xylazine, even if there were little differences in the extent of the effects. The order of the potency was as follows: medetomidine > clonidine > xylazine. Although yohimbine, idazoxan and tolazoline are all selective  $\alpha_2$ -adrenoceptor antagonists, yohimbine was most potent in antagonizing the effect of agonists in the present study. These are consistent with a previous report in which there was a differential ability of these antagonists in blocking the myometrial contractility of xylazine in sows. Yohimbine was approximately 10 times more potent than idazoxan in antagonizing the effect of xylazine in porcine uterine strips<sup>20</sup>. There, however, was an opposite report, in bovine uterine strips, in which yohimbine was approximately 50 times less potent than idazoxan in an-




**Fig 2.** Effect of yohimbine(A), idazoxan(B), and tolazoline(C) on clonidine-induced increase in contractility of isolated porcine myometrial strips in luteal phase of the estrous cycle (n=4-13). Effects are shown in the absence (○) and in the presence of antagonists ( $10^{-8}$ M, ●;  $10^{-7}$ M, ▽;  $10^{-6}$ M, ▲;  $10^{-5}$ M, □). \*p < 0.05, compared with the control group at the corresponding dose of clonidine.

tagonizing the effect of xylazine<sup>21</sup>. It would be interesting to study why there are such differences among species.

On the other hand, prazosin( $10^{-6}$ M), an  $\alpha_1$ -adrenoceptor antagonist, failed to block the contractile effects of these agonists. Our results are consistent with those of a previous report indicating that  $\alpha_2$ -adrenoceptors during the luteal phase of the estrous cycle account for more than 99% of  $\alpha$ -adrenoceptors in porcine myometrium<sup>22</sup>.

Etomidate, at less than  $10^{-6}$ M, did not cause any increase in contractility in our present study. A higher dose of etomidate( $10^{-6}$ M), however, caused an increase in contractility. In addition, the effect of etomidate was blocked by all  $\alpha_2$ -adrenoceptor antagonists we used, but prazosin( $10^{-6}$ M), the  $\alpha_1$ -antagonist, did not block the effect of etomidate. Etomidate activates GABA-gated Cl-channels to induce its CNS effects<sup>23</sup>. However, there is no report regarding activation of  $\alpha_2$ -adrenoceptors by etomidate. It would be interesting to study whether high dose of etomidate can also bind to  $\alpha_2$ -adrenoceptors.

Although clonidine and related imidazole compounds can also bind to imidazole receptors in addition to  $\alpha_2$ -adrenergic binding<sup>4,24,25</sup>, in our present study, clonidine, medetomidine and etomidate caused an increase in myometrial contractility through the activation of  $\alpha_2$ -adrenoceptors. Intracellular free  $\text{Ca}^{2+}$  concentration could be involved in the mediation of myometrial contractility<sup>26,27</sup>. Thus, to evaluate the role of extracellular and intracellular  $\text{Ca}^{2+}$ , we determined whether  $\text{Ca}^{2+}$ -free medium or verapamil, a voltage-dependent  $\text{Ca}^{2+}$  channel blocker<sup>28</sup>, can abolish the effect of agonists. The  $\text{Ca}^{2+}$ -



**Fig 3.** Effect of yohimbine(A), idazoxan(B), and tolazoline(C) on medetomidine-induced increase in contractility of isolated porcine myometrial strips in luteal phase of the estrous cycle(n=4-10). Effects are shown in the absence(○) and in the presence of antagonists( $10^{-8}$ M, ●;  $10^{-7}$ M, ▽;  $10^{-6}$ M, ▼;  $10^{-5}$ M, □). \* $p < 0.05$ , compared with the control group at the corresponding dose of clonidine.

free medium and verapamil, respectively, abolished the effect of clonidine, medetomidine, etomidate, and xylazine on myometrial contractility but only reduced that of carbachol. Our present results suggest that clonidine, medetomidine, etomidate, and xylazine induced the myometrial contractions through exclusively the extracellular  $Ca^{2+}$  influx by opening voltage-dependent  $Ca^{2+}$  channels.

Xylazine and imidazole compounds are frequently used as analgesics and sedatives in veterinary medicine. These

agents can also cause various adverse effects and one of these adverse effects may be abortion, because these agents can increase the myometrial contractility. The present results, therefore, may be of clinical significance because these imidazole compounds and xylazine can modulate the myometrial contractility. Furthermore, the selective antagonists to block the effect of these agents in the uterus can be used to control the untoward reactions such as abortion by use of these agonists.

### Conclusion

In the present study, we evaluated the effect of imidazole compounds on myometrial contractility, in luteal phase, by comparing with that of xylazine. The results of the present study suggest that clonidine, medetomidine, etomidate, and xylazine induced the porcine myometrial contractions through the activation of  $\alpha_2$ -adrenoceptors, and through exclusively the extracellular  $Ca^{2+}$  influx by opening voltage-dependent  $Ca^{2+}$  channels.




Fig 4. Effect of yohimbine(A), idazoxan(B), and tolazoline(C) on xylazine-induced increase in contractility of isolated porcine myometrial strips in luteal phase of the estrous cycle(n=4-12). Effects are shown in the absence(○) and in the presence of antagonists(10<sup>-8</sup>M, ●; 10<sup>-7</sup>M, ▽; 10<sup>-6</sup>M, ▼; 10<sup>-5</sup>M, □). \*p < 0.05, compared with the control group at the corresponding dose of clonidine.

Acknowledgments : Medetomidine and etomidate were donated by Dr. W.H. Hsu.

## References

1. Kamisaki Y, Ishikawa T, Takao Y, *et al.* Binding of [<sup>3</sup>H] P-aminoclonidine to two sites,  $\alpha_2$ -adrenoceptors and imidazoline binding sites: Distribution of imidazoline binding sites in rat brain. *Brain Res*, 514:15-21, 1990.
2. Coupry I, Atlas D, Podevin RA, *et al.* Imidazoline-guanidinium receptive sites in renal proximal tubule: Asymmetric distribution, regulation by cations and interaction with an endogenous clonidine displacing substance. *J Pharmacol Exp Ther*, 252:293-299, 1989.
3. Langin D, Lafontan M. [<sup>3</sup>H] idazoxan binding at non- $\alpha_2$ -adrenoceptors in rabbit adipocyte membranes. *Eur J Pharmacol*, 159:199-203, 1989.
4. Ernsberger P, Giuliano R, Willette RN, *et al.* Hypotensive action of clonidine analogues correlates with binding affinity at imidazole and not alpha-2 adrenergic receptors in the rostral ventrolateral medulla. *J Hypertens*, 6:S554-S557, 1988.
5. Feinland G, Ernsberger P, Meeley MP, *et al.* Differential expression of imidazole and  $\alpha_2$ -adrenergic receptors and clonidine-displacing substance in NG108-15, glial and chromaffin cells. *Soc Neurosci Abstr*, 14: 412, 1988.
6. Vaha-Vahe AT. Clinical evaluation of medetomidine, a novel sedative and analgesic drug for dogs and cats. *Acta Vet Scand*, 30:267-273, 1989.
7. White RJ, Bali S, Bark H. Xylazine and ketamine anaesthesia in the dromedary camel under field conditions. *Vet Rec*, 120:110-113, 1987.
8. Goldstein JA. Clonidine as analgesic. *Biol Psychiat*, 18: 1339, 1983.
9. Domeicke A. Etomidate, a new intravenous hypnotic. *Acta Anesthesiol Belg*, 3:307-315, 1974.
10. Hsu WH, Schaffer DD, Hanson CE. Effects of tolazoline and yohimbine on xylazine-induced central nervous system depression, bradycardia, and tachypnea in sheep. *J Am Vet Med Assoc*, 190:423-426, 1987.
11. Guard CL, Schwark WS. Influence of yohimbine on xylazine-induced depression of central nervous, gastrointestinal and cardiovascular function in the calf. *Cornell Vet*, 77:312-321, 1984.
12. Tranquilli WJ, Thurmon JC, Neff-Davis CA, *et al.* Hyperglycemia and hypoinsulinemia during xylazine-ketamine anesthesia in Thoroughbred horses. *Am J Vet Res*, 45:11-14, 1984.
13. Dobozy VS. Mitaban safety. *DVM*, 13:54-55, 1982.
14. Kyojuka M, Crankshaw DJ, Crankshaw J, *et al.* Alpha-2 adrenoceptors on nervous and muscles of rat uterus. *J Pharmacol Exp Ther*, 244:1128-1138, 1988.
15. Maltier JP, Legand C. Characterization of  $\alpha$ -adrenoceptors in myometrium of preparturient rats. *Eur J Pharmacol*, 117:1-13, 1985.
16. Yang CH, Hsu WH.  $\alpha_2$ -adrenoceptors and voltage-dependent  $Ca^{2+}$  channels are involved in the epinephrine- and norepinephrine-induced increase in porcine myometrial contractility. *Biol Reprod*, 48(Suppl.):158, 1993.
17. Marnet PG, Garcia-Villar R, Laurentie MP, *et al.* *In vivo* pharmacological characterization of alpha adrenergic receptors in sheep myometrium and their physiological meaning. *Biol Reprod*, 37:241-248, 1987.
18. Rodriguez-Martinez H, McKenna D, Weston PG, *et al.* Uterine motility in the cow during the estrous cycle. III. Effects of oxytocin, xylazine, and adrenoceptor blockers. *Theriogenology*, 27:359-368, 1987.
19. Arthur GH, Noakes DE, Pearson H. The estrous cycle and its control. In *Veterinary Reproduction and Obstetrics(Theriogenology)*, 6th ed., Bailliere Tindall, London, pp.23-45, 1989.
20. Ko JCH, Smith BE, Hsu WH. Xylazine enhances porcine myometrial contractility *in vitro*: Possible involvement of  $\alpha_2$ -adrenoceptors and  $Ca^{2+}$  channels. *Biol Reprod*, 43:614-618, 1990.
21. Ko JCH, Hsu WH, Evans LE. The effects of xylazine and alpha-2 adrenoceptor antagonists on bovine uterine contractility *in vitro*. *Theriogenology*. 33:601-611, 1990.

22. Rexroad CE, Guthrie HD. Alpha-adrenergic receptors in myometrium of pregnant and nonpregnant pigs until day 19 proestrus. *Biol Reprod*, 29:615-619, 1983.
  23. Uchida I, Kamachi G, Burt D, *et al.* Etomidate potentiation of GABA<sub>A</sub> receptor gated current depends on the subunit composition. *Neurosci-Lett*, 185:203-206, 1995.
  24. Emsberger P, Kou YR, Prabhakar NR. Imidazole binding sites in the ventrolateral medulla(VLM) and carotid body are labeled by <sup>125</sup>I-p-iodoclonidine(<sup>125</sup>I-PIC): Possible chemosensory role. *FASEB J*, 4:A716, 1990.
  25. Powis DA, Baker DF.  $\alpha_2$ -adrenoceptors do not regulate catecholamine secretion by bovine adrenal chromaffin cells: A study with clonidine. *Mol Pharmacol*, 29:134-141, 1986.
  26. Molnar M, Hertelendy F. Regulation of intracellular free calcium in human myometrial cells by prostaglandin F<sub>2</sub> $\alpha$ : Comparison with oxytocin. *J Clin Endocrinol Metab*, 71:1243-1250, 1990.
  27. Anwer K, Sanborn BM. Changes in intracellular free calcium in isolated myometrial cells: Role of extracellular and intracellular calcium and possible involvement of guanine nucleotide-sensitive proteins. *Endocrinology*, 124:17-23, 1989.
  28. Matthews WD, Jim KF, Hieble JP, *et al.* Postsynaptic  $\alpha$ -adrenoceptors on vascular smooth muscle. *Fed Proc*, 43:2923-2928, 1984.
-